Herpes zoster in old adults;Zona des sujets âgés

Presse Medicale

Volumn 38, Issue 4, 2009, Pages 571-583

  Lang, Pierre Olivier ^a   Belmin, Joël ^b   Michel, Jean Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DULOXETINE; FAMCICLOVIR; GABAPENTIN; HYDROMORPHONE; ORAVIR; OXYCODONE; PREGABALIN; TRAMADOL; UNCLASSIFIED DRUG; VALACICLOVIR; VARICELLA ZOSTER VACCINE; VENLAFAXINE;

CHICKENPOX; DISEASE SEVERITY; GERIATRIC PATIENT; HERPES ZOSTER; HUMAN; INCIDENCE; PAIN; POSTHERPETIC NEURALGIA; PRIMARY PREVENTION; RASH; SHORT SURVEY; VARICELLA ZOSTER VIRUS;

AGED; ANALGESICS; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RISK FACTORS; VIRUS ACTIVATION;

EID: 63649137474     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.05.019     Document Type: Short Survey

References (49)

1. Hope-Simpson R.E. Postherpetic neuralgia. J R Coll Gen Pract 25 (1975) 571-575
2. Kimberlin D.W., and Whitley R.J. Varicella-Zoster vaccine for the prevention of herpes zoster. N Eng J Med 356 (2007) 1338-1343
3. Chidiac C., Buxelles J., Daures J.P., Hoang-Xuan T., Morel P., Leplege A., et al. Characteristics of patients with herpes zoster on presentation to practionners in France. Clin Infect Dis 33 (2001) 62-69
4. Czernichow S., Dupuy A., Flahault A., and Chosidow O. Herpes zoster: enquête d'incidence chez les médecins généralistes du réseau « sentinelles ». Ann Dermatol Venereol 128 (2001) 497-501
5. Gnann J.W., and Whitley R.J. Herpes zoster. N Eng J Med 347 (2002) 340-346
6. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 352 (2005) 2271-2284
7. Gilden D.H., Kleinschmidt-De Masters B.K., La Guardia J.J., Mahalingam R., and Cohrs R.J. Neurologic complications of the reactivation of varicella-zoster virus. N Eng J Med 342 (2000) 635-645
8. Oster G., Harding G., Dukes E., Edelsberg J., and Cleary P.D. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 6 (2005) 356-363
9. Thomas S.L., and Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 4 (2004) 26-33
10. Lang P.O., Herrmann F., and Michel J.P. Varicella-zoster vaccine. N Eng J Med 357 (2007) 89
11. Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 44 (2007) S1-S26
12. Lydick E., Epstein R.S., Himmelberger D., and White C.J. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 45 (2005) S52-S53
13. Fueyo M.A., and Lookingbill D.P. Herpes zoster and occult malignancy. J Am Acad Dermatol 11 (1984) 480-482
14. Melbye M., Goedert J.J., Grossman R.J., and Eyster E. Risks of AIDS after herpes zoster. Lancet 1 (1987) 728-731
15. Galil K., Choo P.W., Donahue J.G., and Platt R. The sequelae of herpes zoster. Arch Intern Med 157 (1997) 1209-1213
16. Kost R.G., and Strauss S.E. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Eng J Med 335 (1996) 32-42
17. Choo P.W., Galil K., Donahue J.G., Walker A.M., Spiegelman D., and Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 157 (1997) 1217-1224
18. Johnson R.W., and Dworkin R.H. Treatment of herpes zoster and postherpetic neuralgia. BMJ 326 (2003) 748-750
19. Pavan-Langston D. Herpes zoster ophthalmicus. Neurology 45 (1995) S50-S51
20. Severson E.A., Baratz K.H., Hodge D.O., and Burke J.P. Herpes zoster ophthalmicus in olmsted county, Minnesota: have systemic antivirals made a difference?. Arch Ophtalmol 121 (2003) 386-390
21. Garweg J., and Böhnke M. Varicella-zoster virus is strongly associated with atypical necrotizing herpetic retinopathies. Clin Infect Dis 24 (1997) 603-608
22. Kezuka T., Sakai J., Usui N., Streilein J.W., and Usui M. Evidence for antigen-specific immune deviation in patients with acute retinal necrosis. Arch Ophtalmol 119 (2001) 1044-1049
23. Lau C.H., Missotten T., Salzmann J., and Lightman S.L. Acute retinal necrosis features, management, and outcomes. Ophthalmology 114 (2007) 756-762
24. Adour K.K. Otological complications of herpes zoster. Ann Neurol 35 (1994) S62-S64
25. Elliott K.J. Other neurological complications of herpes zoster and their management. Ann Neurol 35 (1994) S57-61
26. Dahl H., Marcoccia J., and Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patient. J Clin Microbiol 35 (1997) 345-349
27. Nahass G.T., Goldstein B.A., Zhu W.Y., Serfling U., Penneys N.S., and Leonardi C.L. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and Varicella-zoster infection. JAMA 268 (1992) 2541-2544
28. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, Whitley R.J., Weiss H., Gnann Jr. J.W., Tyring S., Mertz G.J., Pappas P.G., et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann Intern Med 125 (1996) 376-383
29. Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., and Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 330 (1994) 896-900
30. Tyring S.K. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 57 (2007) S136-S142
31. Tyring S.K., Engst R., Corriveau C., Robillard N., Trottier S., Van Slycken S., et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 85 (2001) 576-581
32. Collaborative Famciclovir Herpes Zoster Study Group, Tyring S.K., Barbarash R.A., Nahlik J.E., Cunningham A., Marley J., Heng M., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 89-96
33. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., and Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39 (1995) 1546-1553
34. Jackson J.L., Gibbons R., Meyer G., and Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 157 (1997) 909-912
35. Holten K.B. Treatment of herpes zoster. Am Fam Physician 73 (2006) 882-884
36. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacologic management of neuropatic pain: Evidence-based recommendations. Pain 132 (2007) 237-251
37. Hansson P.T., and Dickenson A.H. Pharmacological treatment of peripheral neuropathic conditions based on shared commodities despite multiple etiologies. Pain 113 (2005) 251-254
38. Jensen M.P., Chodroff M.J., and Dworkin R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68 (2007) 1178-1182
39. Acosta E.P., and Balfour Jr. H.H. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 45 (2001) 2771-2774
40. Attal N. Drug treatment for neuropathic pain. Presse Med 37 2 Pt 2 (2008) 346-353
41. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
42. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002; 50:S205-S24.
43. Hempenstall K., Nurmikko T.J., Johnson R.W., A'Hern R.P., and Rice A.S. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2 (2005) e164
44. Jumaan A.O., Yu O., Jackson L.A., Bohlke K., Galil K., and Seward J.F. Incidence of herpes zoster, before and after varicella-vaccine-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 191 (2005) 2002-2007
45. Urman C.O., and Gottlieb A.B. New viral vaccines for dermatologic disease. J Am Acad Dermatol 58 (2008) 361-370
46. http://www.emea.europa.eu/humandocs/Humans/EPAR/zostavax/zostavax.htm Accès le 22 octobre 2008.
47. Gauthier A., Breuer J., Carrington D., Martin M., and Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 9 (2008) 1-10
48. Schmader K.E., Gnann Jr. J.W., and Watson C.P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 197 Suppl. 2 (2008) S207-S215
49. http://www.sante.gouv.fr/htm/dossiers/cshpf/a_mt_220906_zona.pdf. Accès le 22 octobre 2008.